DLBCL features frequent chromatin gene mutations (EP300, CREBBP, KMT2D, SUZ12, EZH2), suggesting potential disease-halting chromatin interventions [5, 6]. This evidence concerns the gene EZH2 and diffuse large B-cell lymphoma.